Gleevec

$120.00

Each blister contains 10 pills.

Category:

Dosage Forms & Strengths
tablet
100mg
400mg
Acute Lymphoblastic Leukemia
Indicated for adults with relapsed or refractory Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL)

600 mg PO qDay

Myelodysplastic/Myeloproliferative Diseases
Diseases associated with platelet-derived growth factor receptor gene re-arrangements as determined with an FDA-approved test

400 mg PO qDay

Hypereosinophilic Syndrome and/or Chronic Eosinophilic Leukemia
Indicated for patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown

With FIP1L1-PDGFRα fusion kinase mutation: 100 mg PO qDay; may increase to 400 mg qDay in absence of adverse drug reactions if assessments demonstrate insufficient response to therapy

FIP1L1-PDGFRα fusion kinase status negative or unknown: 400 mg PO qDay

Chronic Myeloid Leukemia Philadelphia-Chromosome-positive
Indicated for patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) who are newly-diagnosed in chronic phase, or who are in blast crisis, accelerated phase, or chronic phase after interferon-alpha therapy

Chronic phase (newly-diagnosed)
400 mg PO qDay; may increase to 600 mg/day if tolerated
Chronic phase after failure of interferon-alpha therapy
May increase to 600 mg/day in absence of severe adverse drug reaction and severe nonleukemia related neutropenia or thrombocytopenia as follows
Disease progression (at any time)
Failure to achieve a satisfactory hematologic response after at least 3 months of treatment
Failure to achieve a cytogenetic response after 6-12 months of treatment
Loss of a previously achieved hematologic or cytogenetic response
Accelerated phase or blast crisis
600 mg PO qDay
May increase to 400 mg PO q12hr in absence of severe adverse drug reaction and severe nonleukemia related neutropenia or thrombocytopenia as follows
Disease progression (at any time)
Failure to achieve a satisfactory hematologic response after at least 3 months of treatment
Failure to achieve a cytogenetic response after 6-12 months of treatment
Loss of a previously achieved hematologic or cytogenetic response
Dermatofibrosarcoma Protuberans
Indicated for adults with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans

400 mg PO q12hr

Mastocytosis
Indicated for adults with aggressive systemic mastocytosis without the D816V c-Kit mutation as determined with an FDA-approved test or with c-Kit mutational status unknown

Without D816V c-Kit mutation: 400 mg PO qDay

c-Kit mutational status unknown: 400 mg PO qDay if not responding to other therapies

ASM associated with eosinophilia (a clonal hematological disease related to the fusion kinase FIP1L1-PDGFR-alpha): 100 mg PO qDay initially, may increase to 400 mg/day in absence of adverse effects if response to therapy is insufficient

Gastrointestinal Stromal Tumors
Unresectable and/or metastatic malignant GIST
400 mg PO qDay; may increase to 400 mg BID in patients showing clear signs or symptoms of disease progression at a lower dose and in the absence of severe adverse drug reactions
Adjuvant treatment following complete gross resection of GIST
400 mg PO qDay
In clinical trials, 1 and 3 years of imatinib were studied; therefore, recommended duration is 3 years

Optimal treatment duration is unknown

Dosage Modifications
Withhold treatment if fluid retention

 

Shopping Cart
Scroll to Top